Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Evaluate the IDFS rate, overall survival (OS) rate, and safety profile of UTD2 combined with capecitabine versus capecitabine monotherapy as adjuvant therapy for triple-negative early breast cancer patients who did not achieve pathological complete response (pCR) after neoadjuvant therapy.
Epistemonikos ID: be518f38a69dc95742bb6c9d96d3f2d50a8c2502
First added on: Jun 14, 2025